A study combining microbubble-mediated focused ultrasound and radiation therapy in the healthy rat brain and a F98 glioma model.
Authors: Fletcher SP, Chisholm A, Lavelle M, Guthier R, Zhang Y, Power C, Berbeco R, McDannold N
Focused Ultrasound (FUS) has been shown to sensitize tumors outside the brain to Radiotherapy (RT) through increased ceramide-mediated apoptosis. This study investigated the effects of FUS + RT in healthy rodent brains and F98 gliomas. Tumors, or striata in healthy rats, were targeted with microbubble-mediated, pulsed FUS (220 kHz, 102-444 kPa), followed by RT (4, 8, 15 Gy). FUS + RT (8, 15 Gy) resulted in ablative lesions, not observed with FUS or RT only, in healthy tissue. Lesions were visible using Magnetic Resonance Imaging (MRI) within 72 h and persisted until 21 days post-treatment, indicating potential applications in ablative neurosurgery. In F98 tumors, at 8 and 15 Gy, where RT only had significant effects, FUS + RT offered limited improvements. At 4 Gy, where RT had limited effects compared with untreated controls, FUS + RT reduced tumor volumes observed on MRI by 45-57%. However, survival benefits were minimal (controls: 27 days, RT: 27 days, FUS + RT: 28 days). Histological analyses of tumors 72 h after FUS + RT (4 Gy) showed 93% and 396% increases in apoptosis, and 320% and 336% increases in vessel-associated ceramide, compared to FUS and RT only. Preliminary evidence shows that FUS + RT may improve treatment of glioma, but additional studies are required to optimize effect size.
Introduction
Purpose
Drug delivery with BBB opening
Study Objective
To evaluate the effects of microbubble-mediated pulsed focused ultrasound combined with radiotherapy (FUS + RT) on healthy rat brain tissue and F98 gliomas, including impacts on tumor growth, survival, apoptosis, and ceramide levels.
Animal model / Human subject
Rat (F98 glioma model); strain: not reported; age: not reported; sex: not reported
Disease model
glioma
Targeted brain region(s)
Striatum
Cargo name and characteristics
Radiotherapy (ionizing radiation; doses administered: 4 Gy, 8 Gy, 15 Gy)
Outcomes and Safety
Summary of Outcomes
Microbubble-mediated pulsed FUS (220 kHz, 102–444 kPa) combined with radiotherapy produced persistent ablative lesions in healthy rat brain at 8 Gy and 15 Gy, and in F98 gliomas FUS+RT at 4 Gy reduced tumor volumes by ~45–57% and markedly increased apoptosis and vessel-associated ceramide though survival benefit was minimal. Successful parameters reported: MB-mediated pulsed FUS (220 kHz, 102–444 kPa) + RT at 8 Gy and 15 Gy for brain ablation, and the same FUS + RT at 4 Gy for tumor volume reduction and increased apoptosis/ceramide.
Duration of biological effect
21 days
Safety-related matter
FUS+RT (8 and 15 Gy) produced persistent ablative lesions with tissue removal, scarring, bleaching and edema in healthy rat brains (edema partially resolved by day 10–17), although animals showed no obvious motor or neurological deficits at study endpoint; FUS alone caused transient BBB opening/edema and minor scarring in one animal. In tumor studies, FUS-only and FUS BBB groups showed slightly increased tumor volumes and reduced median survival, suggesting FUS-mediated BBB opening may promote tumor progression and inflammatory effects, so the authors advise caution (e.g., consider anti-inflammatory treatment) when escalating FUS/MB parameters.
Brain Region
Ultrasound Parameters
FUS Frequency
220 kHz
FUS Pressure
0.102-0.444 MPa
FUS Mode
pulsed
Focal Characteristics
focal depth: None; focal length: None; aperture size: None
Treatment frequency
single session
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search